

**Report of the Trustees and  
Unaudited Financial Statements for the Year Ended 31 August 2022  
for  
Pseudomyxoma Survivor**

Harris Lacey and Swain  
Suite 1  
The Riverside Building  
Hessle  
East Yorkshire  
HU13 0DZ

**Pseudomyxoma Survivor**  
**Report of the Trustees**  
**for the Year Ended 31 August 2022**

---

The trustees present their report with the financial statements of the charity for the year ended 31 August 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

**OBJECTIVES AND ACTIVITIES**

**Objectives and aims**

Pseudomyxoma Survivor's main objectives (as set out in the Constitution) are:

- To relieve the sickness, mental and emotional distress of those suffering from pseudomyxoma peritonei (PMP), their families and carers.
- To provide funds to support research into pseudomyxoma peritonei, its causes, treatment and cure and to publish the useful results of such research.
- To promote awareness of pseudomyxoma peritonei.

**Significant activities**

**Main activities undertaken**

The activities that supported the objectives of the Charity during the year were:

- The provision of a website providing advice, information and support.
- The provision of a private Facebook group which has over 1000 members from across the world. Patients are based in predominantly English speaking countries with members worldwide.
- We provided practical as well as emotional support to patients and families through our grant programme and have given financial support to nine families this year.
- The ongoing provision of a Buddy Scheme to provide one to one support to patients and caregivers around the world.

In order to support our patients and their caregivers:

- We have provided access to a family flat in Manchester, to support the families of those patients being treated at The Christie. The flat is managed by the Christie Charitable Fund on our behalf. The flat contains personalised blankets and information about Pseudomyxoma Survivor.
- Christie Hospital Prehabilitation research project - £11,000 donated in March 2022.
- We have supported eighteen families with financial grants
- Ward toiletries were sent to The Christie and Basingstoke.
- Presented to the 2021 online PSOGI conference
- Commenced a programme of regional meetups for patient and caregivers

In order to promote awareness of pseudomyxoma peritonei, Trustees:

- Attended various online sessions hosted by the Small Charities Coalition, National Voices and Findacure
- Attended the Cancer52 meetings online
- Attended relevant EuroPMP meetings
- Promote Rare Disease Day (28th February 2022)
- Co-ordinated a global approach to PMP Awareness Month (August)

Pseudomyxoma Survivor's purpose and its activities contribute to the public benefit through activities to support these objectives.

We are here to help patients understand the treatment options, provide leaflets and online resources that they can trust.

We represent the PMP community through links with other rare disease charities, by attending conferences and by supporting events organised to raise awareness of the disease.

We take pride in the stewardship of our donations which we demonstrated through this year with our committed registration with the Fundraising Regulator.

Pseudomyxoma Survivor has paid due regard to the Charity Commission's general guidance on public benefit when reviewing its aims and objectives and in planning its future activities.

**Pseudomyxoma Survivor**  
**Report of the Trustees**  
**for the Year Ended 31 August 2022**

---

**ACHIEVEMENT AND PERFORMANCE**

**Charitable activities**

Pseudomyxoma is entirely reliant upon donations for our income and due to our very generous supporters we have received £67,193 in donations and other income. We are indebted to all of our fundraisers and their families and friends for their generosity.

This has meant that we have been able to consolidate funds to ensure the sustainability of the charity and are now in a position to be planning to commit to research programmes in the future and to have reserves.

Our Facebook support group goes from strength to strength and we have continued support for the pseudomyxoma peritonei community on RareConnect, a Eurordis initiative which provides a multi-lingual support platform for rare diseases.

We have continued to develop a close working relationship with the teams at the Basingstoke and North Hampshire Hospital and The Christie in Manchester which allows us to better support patients and identify research opportunities.

Once again we are able to retain our status with the Great NonProfits organisation.

**FINANCIAL REVIEW**

**Financial position**

We are extremely pleased that we have total funds of £247,645 at the end of the financial year. With appropriate and controlled governance procedures in place, the trustees continue to be confident that grants and awareness activities can increase the value of the charity to the community.

Pseudomyxoma Survivor's income and expenditure is relatively small and consequently the charity does not have sufficient funds to invest in longer term investments such as stock and shares.

**Reserves policy**

Through prudence in our activities, we are now in a position to be able to ensure that we have a reserve in future years. We will do this through our plan which ensures the charity has reserves to cover our improved grant scheme, basic resources required to keep us 'in business' and to attend conferences where we can represent the voice of the PMP community going forward, for 12 months. With more appropriate and controlled governance procedures in place, the trustees continue to be confident that grants and awareness activities can increase the value of the charity to the community. During the year to 31 August 2022, 12 months' expenditure equated to £32,054, whilst reserves at the period end totalled £247,645.

We have promised funds to other organisations totalling £111,000 as at the year end - 31 August 2022.

- Christie Charitable fund - £15,000 for accommodation as detailed above - awaiting a request for funds.
- Christie Hospital - £11,000 for 2nd stage of the prehabilitation trial, due September 2022.
- Basingstoke Hospital - £35,000 for Molecular study trial. We gave them £15,000 in 2020 and are awaiting a further request for funds as the research develops.
- Norwegian Vaccine Trial - we have promised £50,000 but we haven't agreed a 'contract'/schedule of payment with them yet.

**FUTURE PLANS**

Thanks to our very generous donors, we have plans in place to financially support the following initiatives during the financial year 2022/2023:

- The ongoing provision of family and caregivers accommodation at the Christie Hospital in Manchester.
- The team at Basingstoke Hospital and Southampton University are undertaking a research programme into molecular characterisations of PMP and we will continue financial support of this research.
- We will have discussions with the Christie Hospital in Manchester to continue financially supporting the prehabilitation study.
- We will continue to promote the Family Grants to give financial support where appropriate.
- We will keep in touch with all of our patients and caregivers especially when we know that they are going through stressful situations.

## **Pseudomyxoma Survivor**

### **Report of the Trustees for the Year Ended 31 August 2022**

---

#### **STRUCTURE, GOVERNANCE AND MANAGEMENT**

##### **Governing document**

The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity.

##### **Recruitment and appointment of new trustees**

Trustees are appointed by the existing trustees.

##### **Organisational structure**

In addition to the Trustees we have a group of volunteers who actively undertake the day to day administration of the Facebook group and a further 60 who volunteer as Buddys on the Buddy scheme.

##### **Our people**

Pseudomyxoma Survivor is totally reliant upon volunteers to run and administer the activities of the group. We now have five active Trustees who have a wide range of skills and experience that will enable us to grow and flourish in the future. The Trustees give a huge amount of voluntary time to support the Charity.

Special mention this financial year to all of our volunteers, who help moderate the group and look after the buddies scheme.

Friends of the charity this year that warrant special mention include: Emily Arbuthnot, Peritoneal Malignancy Institute, who ran the London Marathon in aid of Pseudomyxoma Survivor, Duncan Fraser who ran the Ironman in Cork. John Crouch and Kay Standing for their constant support.

#### **REFERENCE AND ADMINISTRATIVE DETAILS**

##### **Registered Charity number**

1143642

##### **Principal address**

9 Ilmington Close  
Hatton Park  
Warwick  
CV35 7TL

##### **Trustees**

Mrs S Oliver  
Mr T Brill (appointed 1.1.23)  
Mrs C Fletcher  
Mrs A C Salisbury  
Mrs A B Brook

##### **Independent Examiner**

Harris Lacey and Swain  
Suite 1  
The Riverside Building  
Hessle  
East Yorkshire  
HU13 0DZ

Approved by order of the board of trustees on ..... 01/06/2023 ..... and signed on its behalf by:

.....  
Mrs A C Salisbury - Trustee

**Independent Examiner's Report to the Trustees of  
Pseudomyxoma Survivor**

---

**Independent examiner's report to the trustees of Pseudomyxoma Survivor**

I report to the charity trustees on my examination of the accounts of Pseudomyxoma Survivor (the Trust) for the year ended 31 August 2022.

**Responsibilities and basis of report**

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act.

**Independent examiner's statement**

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Laura Drew

Harris Lacey and Swain  
Suite 1  
The Riverside Building  
Hessle  
East Yorkshire  
HU13 0DZ

Date: 1<sup>st</sup> June 2023

**Pseudomyxoma Survivor**

**Statement of Financial Activities  
for the Year Ended 31 August 2022**

		2022	2021
		Unrestricted	Total funds
	Notes	fund	£
		£	£
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies		67,193	73,196
		<hr/>	<hr/>
<b>EXPENDITURE ON</b>			
Raising funds	2	4,128	4,544
<b>Charitable activities</b>	3		
Charitable activities		10,873	3,618
Grant making		15,397	12,358
Support costs		1,656	1,048
		<hr/>	<hr/>
<b>Total</b>		32,054	21,568
		<hr/>	<hr/>
<b>NET INCOME</b>		35,139	51,628
		<hr/>	<hr/>
<b>RECONCILIATION OF FUNDS</b>			
Total funds brought forward		212,506	160,878
		<hr/>	<hr/>
<b>TOTAL FUNDS CARRIED FORWARD</b>		247,645	212,506
		<hr/> <hr/>	<hr/> <hr/>


The notes form part of these financial statements

Pseudomyxoma Survivor

**Balance Sheet**  
**31 August 2022**

		2022 Unrestricted fund £	2021 Total funds £
<b>CURRENT ASSETS</b>	Notes		
Debtors	10	180	150
Cash at bank		250,141	213,841
		<u>250,321</u>	<u>213,991</u>
<b>CREDITORS</b>			
Amounts falling due within one year	11	(2,676)	(1,485)
		<u>247,645</u>	<u>212,506</u>
<b>NET CURRENT ASSETS</b>			
		<u>247,645</u>	<u>212,506</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<u>247,645</u>	<u>212,506</u>
<b>NET ASSETS</b>		<u>247,645</u>	<u>212,506</u>
<b>FUNDS</b>	12		
Unrestricted funds		247,645	212,506
<b>TOTAL FUNDS</b>		<u>247,645</u>	<u>212,506</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 01/06/2023 and were signed on its behalf by:

  
Mrs A C Salisbury - Trustee

The notes form part of these financial statements

**Notes to the Financial Statements  
for the Year Ended 31 August 2022**

---

**1. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

**Income**

Income received for services provided is accounted for on an accruals basis.

Cash donations, gifts and legacies are included in full in the income and expenditure account as they are received. Any significant non-cash donations are included in the income and expenditure account at the trustees' estimate of their market value when received. The value of voluntary help is not included in the accounts.

Grants and other funding of a revenue nature are deferred and released to the income and expenditure account over the period to which they relate.

Bank interest is included in the income and expenditure account on an accruals basis.

**Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment        - 33% on cost

**Taxation**

The charity is exempt from tax on its charitable activities.

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.



**Pseudomyxoma Survivor**

**Notes to the Financial Statements - continued  
for the Year Ended 31 August 2022**

**1. ACCOUNTING POLICIES - continued**

**Estimates and judgements**

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Although these estimates are based on the Directors' best knowledge of the amount, events or actions, actual results ultimately differ from these estimates. The Directors do not consider there to be any material estimates and judgements.

**Financial instruments**

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments, including trade and other debtors and creditors, are initially recognised at transaction value and subsequently measured at their settlement value.

**2. RAISING FUNDS**

**Raising donations and legacies**

	2022	2021
	£	£
Just Giving	1,418	1,373
Costs of generating funds	2,710	3,171
	<u>4,128</u>	<u>4,544</u>

**3. CHARITABLE ACTIVITIES COSTS**

	Direct Costs £	Grant funding of activities (see note 4) £	Support costs (see note 5) £	Totals £
Charitable activities	10,873	-	-	10,873
Grant making	-	15,397	-	15,397
Support costs	-	-	1,656	1,656
	<u>10,873</u>	<u>15,397</u>	<u>1,656</u>	<u>27,926</u>

**4. GRANTS PAYABLE**

	2022	2021
	£	£
Grant making	<u>15,397</u>	<u>12,358</u>

**Pseudomyxoma Survivor**

**Notes to the Financial Statements - continued  
for the Year Ended 31 August 2022**

**5. SUPPORT COSTS**

	Governance costs £
Support costs	1,656

Support costs, included in the above, are as follows:

	2022 Support costs £	2021 Total activities £
Independent examination	1,656	1,020
Accountancy and legal fees	-	28
	<u>1,656</u>	<u>1,048</u>

**6. TRUSTEES' REMUNERATION AND BENEFITS**

There was trustees' remuneration totalling £8,640 but no other benefits for the year ended 31 August 2022, with no trustees' remuneration or other benefits for the year ended 31 August 2021.

The remuneration was received by Mrs S Oliver for their role as the Charity's administrator, after much consideration by the board as to how to fill this role. This was recorded in the Charity's board meeting minutes.

**Trustees' expenses**

There were no trustees' expenses paid for the year ended 31 August 2022 nor for the year ended 31 August 2021.

**7. STAFF COSTS**

There were no staff costs for the year ended 31 August 2022 nor for the year ended 31 August 2021.

The average number of employees during the year was NIL (2021 - NIL).

No employees received emoluments in excess of £60,000.

**8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**

	Unrestricted fund £
<b>INCOME AND ENDOWMENTS FROM</b>	
Donations and legacies	73,196
<b>EXPENDITURE ON</b>	
Raising funds	4,544
<b>Charitable activities</b>	
Charitable activities	3,618
Grant making	12,358
Support costs	1,048
<b>Total</b>	<u>21,568</u>

**Pseudomyxoma Survivor**

**Notes to the Financial Statements - continued  
for the Year Ended 31 August 2022**

<b>8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued</b>		Unrestricted fund £
		<u>£</u>
	<b>NET INCOME</b>	51,628
	<b>RECONCILIATION OF FUNDS</b>	
	Total funds brought forward	160,878
	<b>TOTAL FUNDS CARRIED FORWARD</b>	<u>212,506</u>
<b>9. TANGIBLE FIXED ASSETS</b>		Computer equipment £
	<b>COST</b>	
	At 1 September 2021	379
	Disposals	(379)
		<u>-</u>
	At 31 August 2022	-
	<b>DEPRECIATION</b>	
	At 1 September 2021	379
	Eliminated on disposal	(379)
		<u>-</u>
	At 31 August 2022	-
	<b>NET BOOK VALUE</b>	
	At 31 August 2022	<u>-</u>
	At 31 August 2021	<u>-</u>
<b>10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR</b>		
		2022      2021
		£      £
	Trade debtors	-      150
	Prepayments and accrued income	180      -
		<u>180      150</u>

Pseudomyxoma Survivor

Notes to the Financial Statements - continued  
for the Year Ended 31 August 2022

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022	2021
	£	£
Trade creditors	1,020	465
Other creditors	1,656	1,020
	<u>2,676</u>	<u>1,485</u>

12. MOVEMENT IN FUNDS

	At 1.9.21	Net movement in funds	At 31.8.22
	£	£	£
<b>Unrestricted funds</b>			
General fund	212,506	35,139	247,645
	<u>212,506</u>	<u>35,139</u>	<u>247,645</u>
<b>TOTAL FUNDS</b>	<u>212,506</u>	<u>35,139</u>	<u>247,645</u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
<b>Unrestricted funds</b>			
General fund	67,193	(32,054)	35,139
	<u>67,193</u>	<u>(32,054)</u>	<u>35,139</u>
<b>TOTAL FUNDS</b>	<u>67,193</u>	<u>(32,054)</u>	<u>35,139</u>

Comparatives for movement in funds

	At 1.9.20	Net movement in funds	At 31.8.21
	£	£	£
<b>Unrestricted funds</b>			
General fund	160,878	51,628	212,506
	<u>160,878</u>	<u>51,628</u>	<u>212,506</u>
<b>TOTAL FUNDS</b>	<u>160,878</u>	<u>51,628</u>	<u>212,506</u>

**Pseudomyxoma Survivor**

**Notes to the Financial Statements - continued  
for the Year Ended 31 August 2022**

**12. MOVEMENT IN FUNDS - continued**

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	73,196	(21,568)	51,628
<b>TOTAL FUNDS</b>	<u>73,196</u>	<u>(21,568)</u>	<u>51,628</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.9.20 £	Net movement in funds £	At 31.8.22 £
<b>Unrestricted funds</b>			
General fund	160,878	86,767	247,645
<b>TOTAL FUNDS</b>	<u>160,878</u>	<u>86,767</u>	<u>247,645</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	140,389	(53,622)	86,767
<b>TOTAL FUNDS</b>	<u>140,389</u>	<u>(53,622)</u>	<u>86,767</u>

**13. RELATED PARTY DISCLOSURES**

There were no related party transactions for the year ended 31 August 2022.